Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of inactivated COVID-19 vaccine in adults with vital organ damage
ChiCTR2100054400Phase 4Not yet recruiting
- Sponsor
- China National Biotec Group
- Start
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of turkovac in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by China National Biotec Group. Primary endpoints: Four-fold increase rate and level of anti-SARS-CoV-2 antibodies and Geometric mean titer and four-fold increase rate of IgG antibody. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
turkovac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100054400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054400.